KRAS G12D-mutations–common drivers of pancreatic cancer (~40%) and also present in non-small cell lung cancer (5%)–can now be targeted with the first-in-class protein degrader setidegrasib, achieving in a phase 1 trial response rates of 19–24% for pancreatic cancer 36% for NSCLC among heavily pretreated patients. | Park, N Engl J Med 2026
